Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vectibix clinical trials (correction)

Executive Summary

Amgen said it is continuing to study Vectibix (panitumumab), which failed to show survival benefits in a Phase IIIb trial, as a single biologic combined with chemotherapy in two Phase III trials in the first-and second-line of metastatic colorectal cancer. A previous article suggests that Vectibix failed to show survival benefits in a Phase IV commitment (1"The Pink Sheet" Aug. 20, 2007, p. 16). Phase IV commitments for Vectibix are progressing well, notably the registrational Phase III trial in the second-line of metastatic colorectal cancer, Amgen says...

You may also be interested in...



Accelerated “De-proval”? FDA May Be Ready To Withdraw Subpart H Drug

FDA is moving towards potentially withdrawing, for the first time, a drug brought to market under the Subpart H accelerated approval mechanism

Lilly Looks To Accelerate Tirzepatide Into Obesity With Rolling Submission

Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.

EU To Expand Fragrance Allergen Labeling With Implications For California’s ‘Right To Know’

Companies will have more fragrance allergens to report to California health authorities if the European Union requires more than 50 additional fragrance allergens to be labeled on cosmetic products, as proposed by the Commission in September.

Latest News
See All
UsernamePublicRestriction

Register

PS048757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel